Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects
Abstract Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are the most common causes of emotional distress that impair an individual's quality of life. MDD is a chronic mental illness that affects 300 million people across the world. Clinical manifestations of MDD includ...
Main Authors: | Bhuvi Sachdeva, Punya Sachdeva, Shampa Ghosh, Faizan Ahmad, Jitendra Kumar Sinha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley-VCH
2023-03-01
|
Series: | Ibrain |
Subjects: | |
Online Access: | https://doi.org/10.1002/ibra.12094 |
Similar Items
-
Anesthesia, the developing brain, and dexmedetomidine for neuroprotection
by: Alexandra Tsivitis, et al.
Published: (2023-06-01) -
Neuroinflammation and major depressive disorder: astrocytes at the crossroads
by: Melissa Puentes-Orozco, et al.
Published: (2024-11-01) -
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
by: Caroline Ann Browne, et al.
Published: (2013-12-01) -
Neuroplasticity in Depressive Disorders: The Role of BDNF in Linking Pharmacotherapy and Physical Activity
by: Maciej Mamczur, et al.
Published: (2024-12-01) -
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
by: Bangshan Liu, et al.
Published: (2017-09-01)